New research indicates that smoking significantly raises the likelihood of developing pancreatic cancer, one of the deadliest forms of the disease.
Known as a ‘silent killer’ due to its mild symptoms, pancreatic cancer claims over 10,000 lives annually in the UK—roughly one every hour.
Looking ahead, projections suggest that by 2040, there could be 201,000 new cases, representing a striking increase.
This cancer is often diagnosed too late because its early warning signs can easily be confused with other health issues.
In light of this, researchers from the US recommend that general practitioners pay closer attention to smokers when it comes to screening for pancreatic cancer.
Professor Timothy Frankel, a leading surgical oncologist on the study, emphasized that smokers should receive better education about potential symptoms and possibly be referred to specialized clinics.
A study detailed in the journal Cancer Discovery from the University of Michigan Health Rogel Cancer Centre identified a specific immune cell that reacts to cancer-causing toxins in cigarettes.
The research involved exposing mice with pancreatic tumors to these toxic substances to observe their effects.
One focus was on a protein called Interleukin 22 (IL22), which has a known role in tumor growth.
The findings revealed that the toxin significantly altered tumor behavior, accelerating cancer progression.
“The changes were quite pronounced,” Prof. Frankel noted, adding that the tumors became larger and spread more aggressively.
Interestingly, in mice without immune systems, the carcinogen did not impact tumor growth.
This led researchers to conclude that the carcinogen enhances tumor growth through immune system mechanisms.
They identified a type of immune cell—T-regulatory cells (Tregs)—as crucial in this process.
These Tregs both produce IL22 and dampen the body’s natural defenses against tumors.
Prof. Frankel described this as a ‘two-pronged attack.’ He mentioned that eradicating Treg cells in specific mouse models reversed the tumor growth induced by the cigarette chemicals.
The researchers supported their results using human cells, observing that smokers with pancreatic cancer had a higher quantity of Tregs compared to non-smokers, a change attributed to increased IL22 levels from the toxins.
They also noted that an inhibitor capable of blocking these harmful chemicals effectively reduced tumor size.
As Prof. Frankel put it, tackling the suppressive cells might enhance the body’s anti-tumor immunity.
This could further be boosted by existing immunotherapy treatments, which often struggle in pancreatic cancer due to the immunosuppressive environment.
There’s still a lot to explore about the potential uses of these inhibitors, but this research opens up new avenues for treating pancreatic cancer patients who are smokers.
If detected early, before metastasis, about half of pancreatic cancer patients are likely to survive for at least a year.
However, once the cancer has spread, only around 10% of patients will see that milestone.
While the risk of pancreatic cancer rises significantly with age, especially for those over 75, younger individuals can also be affected.
Notably, a recent report highlighted a troubling increase in pancreatic cancer among young women, with rates rising by up to 200% in those under 25 since the 1990s.
This trend is puzzling as no similar rise has been noted in men of the same age group.
Overall, pancreatic cancer incidences have increased by about 17% in the UK, with factors like obesity and environmental issues contributing to this rise.
Some potential symptoms of pancreatic cancer include jaundice—manifesting as yellowing of the eyes and skin—as well as itchy skin and darker urine.
Other signs might consist of loss of appetite, unintended weight loss, constipation, or bloating. It’s advisable to consult a GP if these symptoms persist for over four weeks.
The pancreas, about 25 cm long, plays a vital role in digestion and hormone regulation, sitting just behind the stomach.
According to Cancer Research UK, smoking is responsible for about 22% of pancreatic cancer cases, with obesity contributing to another 12%.
